IFIH1 and interstitial lung disease: Regarding anti-MDA5 antibodies, patients had a slightly elevated but not significant risk of ILD (adjusted OR = 2.86, 95% CI: 0.75–10.86; p = 0.124) compared to those without anti-MDA5 antibodies.